Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Scopolamine + propofol is a combination of two pharmaceutical agents used together, typically in the context of anesthesia or procedural sedation. Scopolamine is a belladonna alkaloid with anticholinergic properties, primarily used to prevent nausea and vomiting associated with motion sickness and postoperative states. It acts as an antagonist at muscarinic acetylcholine receptors, thereby inhibiting cholinergic transmission in the central nervous system and peripheral tissues[4][8]. Propofol is an intravenous anesthetic agent used for induction and maintenance of general anesthesia or sedation. It works mainly by potentiating GABA-A receptor activity, leading to CNS depression[1][3]. When combined, scopolamine may be administered as a premedication to reduce secretions and prevent nausea/vomiting during procedures where propofol provides rapid-onset hypnosis/sedation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on scopolamine + propofol.